Healthpeak Reports Mixed Q4 & FY25 Results, Issues 2026 Guidance, and Progresses Senior Housing IPO

summarizeSummary

Healthpeak Properties reported mixed Q4 and full-year 2025 results, issued conservative 2026 guidance, and provided an update on its strategic initiatives, including the planned IPO of its senior housing portfolio and significant capital recycling activities.

check_boxKey Events

• Q4 & Full Year 2025 Financial Performance

  Reported Q4 2025 net income of $0.16 per share (up from $0.01 in Q4 2024) and Nareit FFO of $0.47 per share (up from $0.44). Full-year 2025 net income was $0.10 per share (down from $0.36 in FY 2024), with Nareit FFO of $1.81 per share (up from $1.61).

• 2026 Financial Guidance Issued

  Provided 2026 guidance for diluted EPS of $0.34-$0.38, diluted Nareit FFO per share of $1.70-$1.74, and diluted FFO as Adjusted per share of $1.70-$1.74. Total Merger-Combined Same-Store Cash (Adjusted) NOI growth is projected at (1%) to 1%.

• Janus Living IPO Progressing

  Announced the formation and planned initial public offering (IPO) of Janus Living, Inc., a REIT dedicated to senior housing, with a confidential draft registration statement on Form S-11 submitted in December 2025. The IPO is expected to be completed in the first half of 2026.

• Significant Capital Allocation Activities

  Acquired a 1.4 million square foot campus in South San Francisco for $600 million and the remaining 46.5% joint venture interest in a 19-community senior housing portfolio for $314 million. The company plans $1 billion in asset sales, recapitalizations, and loan repayments in 2026, including $325 million in outpatient medical sales and a $68 million lab campus sale in early 2026.

auto_awesomeAnalysis

Healthpeak Properties announced mixed financial results for Q4 and full-year 2025, alongside a strategic update that includes the planned IPO of Janus Living, Inc., a senior housing REIT. While Q4 2025 saw a significant increase in net income and solid same-store NOI growth, the full-year 2025 net income declined. The 2026 guidance indicates a substantial increase in diluted EPS but a decrease in FFO and AFFO per share, with same-store NOI growth projected to be flat to slightly positive (0% to 1%). This low NOI guidance, particularly the negative outlook for the lab segment, suggests near-term operational challenges. However, the company is actively reshaping its portfolio through significant acquisitions in life science and senior housing, and a $1 billion capital recycling plan, aiming to unlock value and focus on higher-growth opportunities. The unencumbering of the senior housing portfolio is a positive balance sheet development.